Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients

Table 2

RAVs to HCV NS3/4A inhibitors.

Resistance mutations	Drugs	References	Detected resistance mutations; (HCV 6a )	Detected resistance mutations; (HCV 1b )
V36 A/G/ C/L	Boceprevir, paritaprevir, telaprevir	[13, 26]	V36L 4.5% (4/88)	—
T54A/S	Boceprevir, telaprevir	[13, 26, 27]	—	T54S 6.67% (4/60)
V55A	Boceprevir, telaprevir	[13]	—	V55R 1.67% (1/60)
Q80R/K	Asunaprevir, paritaprevir, simeprevir	[13, 14, 28]	Q80K 95.5% (84/88)	Q80L 3.33% (2/60)
R155K/T/Q/I/M/G/L/S	Asunaprevir, boceprevir, paritaprevir, simeprevir, telaprevir	[13, 14, 26]	—	—
A156F/N/S/T/V	Asunaprevir, boceprevir, paritaprevir, simeprevir, telaprevir	[13, 14, 27–29]	—	A156S 18.33% (11/60)
D168G/V/E/H/T/Y	Asunaprevir, Paritaprevir, Simeprevir	[13, 14, 27, 29]	D168E 2.3% (2/88)	D168Y 1.67% (1/60)
V170A	Boceprevir, telaprevir	[13]	V170I 98.8% (87/88)	V170I 15.0% (9/60)
F43I/L/S/V	Asunaprevir, paritaprevir, simeprevir	[14, 19, 27, 29]	—	—
Y56H	Paritaprevir	[13, 14]	—	—
S122R	Asunaprevir, simeprevir	[14]	—	—
V158I	Boceprevir	[13, 26]	—	—
M175L	Boceprevir	[13, 26]	—	—